204 related articles for article (PubMed ID: 19785057)
1. Clinical relevance of monoclonal antibodies in non small cell lung cancer.
Filipits M
J BUON; 2009 Sep; 14 Suppl 1():S147-52. PubMed ID: 19785057
[TBL] [Abstract][Full Text] [Related]
2. Monoclonal antibodies against EGFR in non-small cell lung cancer.
Pirker R; Filipits M
Crit Rev Oncol Hematol; 2011 Oct; 80(1):1-9. PubMed ID: 21109448
[TBL] [Abstract][Full Text] [Related]
3. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
4. New antiangiogenetic agents and non-small cell lung cancer.
Gridelli C; Rossi A; Maione P
Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
[TBL] [Abstract][Full Text] [Related]
5. Combining targeted therapies and drugs with multiple targets in the treatment of NSCLC.
Maione P; Gridelli C; Troiani T; Ciardiello F
Oncologist; 2006 Mar; 11(3):274-84. PubMed ID: 16549812
[TBL] [Abstract][Full Text] [Related]
6. [Stage IV NSCLC. Biological treatments of lung cancer in 2008... and in the near future].
Bergot E; Levallet G; Zalcman G
Rev Mal Respir; 2008 Oct; 25(8 Pt 2):3S119-26. PubMed ID: 18971836
[TBL] [Abstract][Full Text] [Related]
7. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
Pennell NA; Lynch TJ
Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
Raben D; Helfrich B; Bunn PA
Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
[TBL] [Abstract][Full Text] [Related]
9. Optimizing first-line treatment options for patients with advanced NSCLC.
Wakelee H; Belani CP
Oncologist; 2005; 10 Suppl 3():1-10. PubMed ID: 16368866
[TBL] [Abstract][Full Text] [Related]
10. The potential of antiangiogenic therapy in non-small cell lung cancer.
Giaccone G
Clin Cancer Res; 2007 Apr; 13(7):1961-70. PubMed ID: 17404076
[TBL] [Abstract][Full Text] [Related]
11. Is there still room for large registrative trials in unselected cancer patients? The case of anti-epidermal growth factor receptor antibodies in advanced non-small-cell lung cancer.
Di Maio M
Expert Opin Biol Ther; 2011 Sep; 11(9):1131-3. PubMed ID: 21806477
[TBL] [Abstract][Full Text] [Related]
12. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine.
García B; Neninger E; de la Torre A; Leonard I; Martínez R; Viada C; González G; Mazorra Z; Lage A; Crombet T
Clin Cancer Res; 2008 Feb; 14(3):840-6. PubMed ID: 18245547
[TBL] [Abstract][Full Text] [Related]
13. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go.
Patel JD; Pasche B; Argiris A
Crit Rev Oncol Hematol; 2004 Jun; 50(3):175-86. PubMed ID: 15182824
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic therapy in nonsmall cell lung cancer.
Gutierrez M; Giaccone G
Curr Opin Oncol; 2008 Mar; 20(2):176-82. PubMed ID: 18300767
[TBL] [Abstract][Full Text] [Related]
15. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier.
Sangha R; Lara PN; Mack PC; Gandara DR
Curr Opin Oncol; 2009 Mar; 21(2):116-23. PubMed ID: 19532012
[TBL] [Abstract][Full Text] [Related]
16. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.
Sandler AB; Johnson DH; Herbst RS
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4258s-4262s. PubMed ID: 15217970
[TBL] [Abstract][Full Text] [Related]
17. The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments.
Gridelli C; Maione P; Rossi A; De Marinis F
Oncologist; 2007 Oct; 12(10):1183-93. PubMed ID: 17962612
[TBL] [Abstract][Full Text] [Related]
18. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
[TBL] [Abstract][Full Text] [Related]
19. The evolving role of cetuximab in non-small cell lung cancer.
Lilenbaum RC
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4432s-4435s. PubMed ID: 16857823
[TBL] [Abstract][Full Text] [Related]
20. Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.
Gridelli C; Ardizzoni A; Douillard JY; Hanna N; Manegold C; Perrone F; Pirker R; Rosell R; Shepherd FA; De Petris L; Di Maio M; de Marinis F
Lung Cancer; 2010 Jun; 68(3):319-31. PubMed ID: 20036027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]